OSD
Myeloma is a very individual cancer, both in terms of what symptoms and complications patients can have and in the way they respond to treatment. Improvements made to treatment over the last decade have meant that survival rates are increasing, however there is still no cure and there remains a significant need for more efficacious and tolerable therapies.
Collaboration between Oncopeptides and Recipharm means that a new drug product to treat multiple myeloma is getting closer to a reality every day.
Discover how by registering below to download the full case study.